The aims of this investigation were to clarify fetal methylation status at CpG sites of the promoter of HSD11B2 in preeclampsia and normal pregnancy, and discuss the possible role of alteration in methylation at the promoter of HSD11B2 in programming of the risk of metabolic diseases in the adulthood of the offspring of preeclampsia. The gene discussed is HSD11B2; the disease is metabolic disease.